Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 17/20 | 0.80 |
| ▸ | MMP2 | P08253 | 6/20 | 0.80 |
| ▸ | MMP3 | P08254 | 6/20 | 0.80 |
| ▸ | MMP9 | P14780 | 6/20 | 0.80 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6723167 | 0.89 | MMP13 (1.00) | MMP13MMP2MMP3MMP9 | |
| SCHEMBL6731065 | 0.88 | MMP13 (1.00) | MMP13MMP2MMP3MMP9 | |
| SCHEMBL12336942 | 0.84 | MMP13 (1.00) | MMP13MMP2MMP3MMP9 | |
| SCHEMBL6727253 | 0.81 | MMP13 (0.76) | MMP13MMP2MMP3MMP9 | |
| SCHEMBL6719742 | 0.80 | MMP13 (0.73) | MMP13MMP2MMP3MMP9 | |
| SCHEMBL6727173 | 0.80 | MMP13 (0.73) | MMP13MMP2MMP3MMP9 | |
| SCHEMBL6724029 | 0.79 | MMP13 (1.00) | MMP13MMP2MMP3MMP9 | |
| SCHEMBL6724183 | 0.78 | MMP13 (1.00) | MMP13MMP2MMP3MMP9L3MBTL1 | |
| SCHEMBL6727168 | 0.78 | MMP13 (0.86) | MMP13MMP2MMP3MMP9 | |
| SCHEMBL6727261 | 0.77 | MMP13 (0.67) | MMP13MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024001-A1 | Spirobarbituric acid derivatives useful as inhibitors of matrix metalloproteases | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-05 | — | — | US | claimed |
| WO-2003091252-A1 | SPIROBARBITURIC ACID DERIVATIVES USEFUL AS INHIBITORS OF MATRIX METALLOPROTEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024001-A1 | Spirobarbituric acid derivatives useful as inhibitors of matrix metalloproteases | MMP13, MMP3, MMP1 | MMP13 1/4885MMP2 13/4885MMP3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.